BioSpace News Archive

Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima®.

Can-Fite BioPharma Ltd today announced that it submitted a pediatric study plan to the U.S. Food and Drug Administration (FDA) for the treatment of adolescents suffering from psoriasis with Piclidenoson.

Satio is pleased to announce a contract awarded by the Biomedical Advanced Research and Development Authority ( BARDA ), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to develop a novel, single-use, rapid ebolavirus diagnostic.

Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center.

DENTSPLY SIRONA Inc. announced that the Company will participate in the Baird 2023 Global Healthcare Conference.

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces its next generation Cochlear™ Osia® System with the ability to have an MRI at 3.0 T, designed to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD).

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 150,938 shares of its common stock to 8 newly hired employees, consisting of inducement stock options to purchase an aggregate of 86,250 shares of common stock and inducement restricted stock units, covering an aggregate of 64,688 shares of its common stock.

Calliditas Therapeutics AB, announced that the U.S. Food and Drug Administration has accepted the submission for the supplemental New Drug Application for TARPEYO® delayed release capsules and granted Priority Review.

Inmagene Biopharmaceuticals announced topline results from a Phase 1 study of IMG-007, an anti-OX40 monoclonal antibody (mAb).